Effects of the Magenstrasse and Mill operation for obesity on plasma plasminogen activator inhibitor type 1, tissue plasminogen activator, fibrinogen and insulin

被引:7
|
作者
Carmichael, AR
Tate, G
King, RFG
Sue-Ling, HM
Johnston, D
机构
[1] Leeds Gen Infirm, Acad Dept Surg, Leeds, W Yorkshire, England
[2] Leeds Gen Infirm, Dept Haematol, Leeds, W Yorkshire, England
关键词
obesity; fibrinolysis; fibrinogen; insulin;
D O I
10.1159/000057287
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Plasminogen activator inhibitor 1 (PAI-1), tissue plasminogen activator (t-PA), fibrinogen and insulin were measured in 43 patients 3 years after they had undergone the Magenstrasse and Mill (MM) procedure and in 43 morbidly obese (MO) patients. Mean plasma PAI-1 was 61 ng/ml in the MO group compared to 30 ng/ml in the MM group (p < 0.0001); mean plasma t-PA was 10 ng/ml in the MO group compared to 7 ng/ml in the MM group (p < 0.001). Mean fibrinogen was 3.6 g/l in the MO group compared to 3.2 g/l in the MM group (p < 0.05). Mean plasma insulin levels were 32 U/ml in the MO group compared to 15 U/ml in the MM group. These changes suggest that use of the MM procedure may reduce mortality and morbidity from coronary heart disease in these high-risk obese patients. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:40 / 43
页数:4
相关论文
共 50 条
  • [21] NORMAL TISSUE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR ACTIVITY IN PLASMA FROM PATIENTS WITH TYPE-1 DIABETES-MELLITUS
    VICARI, AM
    DANGELO, SV
    TESTA, S
    COMI, G
    GALARDI, G
    ORSI, E
    DANGELO, A
    HORMONE AND METABOLIC RESEARCH, 1992, 24 (11) : 516 - 519
  • [22] Increased plasma fibrinolysis and tissue-type plasminogen activator/tissue-type plasminogen activator inhibitor ratios after ethanol withdrawal in chronic alcoholics
    Delahousse, B
    Maillot, F
    Gabriel, I
    Schellenberg, F
    Lamisse, F
    Gruel, Y
    BLOOD COAGULATION & FIBRINOLYSIS, 2001, 12 (01) : 59 - 66
  • [23] Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients
    Fogari, R
    Mugellini, A
    Zoppi, A
    Corradi, L
    Preti, P
    Lazzari, P
    Derosa, G
    AMERICAN JOURNAL OF HYPERTENSION, 2002, 15 (04) : 316 - 320
  • [24] Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in diabetic foot syndrome
    Kulwas, Arleta
    Lisewska, Beata
    Jundzill, Wieslaw
    Ruszkowska, Barbara
    Drewniak, Wanda
    Ruprecht, Zofia
    Gadomska, Grazyna
    Rosc, Danuta
    ADVANCES IN MEDICAL SCIENCES, 2017, 62 (01): : 87 - 91
  • [25] Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
    Al-Hamodi, Zaid
    Ismail, Ikram S.
    Saif-Ali, Riyadh
    Ahmed, Khaled A.
    Muniandy, Sekaran
    CARDIOVASCULAR DIABETOLOGY, 2011, 10
  • [26] Increased concentration of plasminogen activator inhibitor-1 and fibrinogen in individuals with metabolic syndrome
    Palomo, Ivan G.
    Gutierrez, Cesar L.
    Alarcon, Marcelo L.
    Jaramillo, Julio C.
    Segovia, Fabian M.
    Leiva, Elba M.
    Mujica, Veronica E.
    Icaza, Gloria N.
    Diaz, Nora S.
    Moore-Carrasco, Rodrigo
    MOLECULAR MEDICINE REPORTS, 2009, 2 (02) : 253 - 257
  • [27] Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome
    Lindholm, Asa
    Bixo, Marie
    Eliasson, Mats
    Hudecova, Miriam
    Arnadottir, Ragnheidur
    Holte, Jan
    Poromaa, Inger Sundstrom
    GYNECOLOGICAL ENDOCRINOLOGY, 2010, 26 (10) : 743 - 748
  • [28] Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator
    Shenkman, Boris
    Livnat, Tami
    Budnik, Ivan
    Tamarin, Ilia
    Einav, Yulia
    Martinowitz, Uriel
    BLOOD COAGULATION & FIBRINOLYSIS, 2012, 23 (08) : 729 - 733
  • [29] Structural Basis for Recognition of Urokinase-type Plasminogen Activator by Plasminogen Activator Inhibitor-1
    Lin, Zhonghui
    Jiang, Longguang
    Yuan, Cai
    Jensen, Jan K.
    Zhang, Xu
    Luo, Zhipu
    Furie, Barbara C.
    Furie, Bruce
    Andreasen, Peter A.
    Huang, Mingdong
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (09) : 7027 - 7032
  • [30] EFFECT OF ORAL DEFIBROTIDE ON TISSUE-PLASMINOGEN ACTIVATOR AND TISSUE-PLASMINOGEN ACTIVATOR INHIBITOR BALANCE
    VIOLI, F
    FERRO, D
    SALIOLA, M
    QUINTARELLI, C
    BASILI, S
    BALSANO, F
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 42 (04) : 379 - 383